Clinical Research Directory

Inclusion Criteria: 1. Male, aged 18 to 85 years. 2. Histologically confirmed prostate adenocarcinoma, without small cell carcinoma components. 3. Metastatic Castration-Resistant Prostate Cancer (mCRPC) with disease progression after at least one novel endocrine therapy (e.g., abiraterone or enzalutamide) and/or docetaxel chemotherapy. 4. Evidence of bone metastasis on PSMA-PET-CT or bone scan (ECT). 5. Serum testosterone at castration levels (\< 50 ng/dL or 1.75 nmol/L). 6. ECOG performance status ≤ 2. 7. Life expectancy \> 6 months. 8. Adequate bone marrow, hepatic, and renal function. 9. Willing to undergo biopsies before and during treatment Exclusion Criteria: 1. Lack of pathological evidence for prostate cancer. 2. Other primary malignant tumors active or requiring treatment within the past 3 years. 3. Has visceral metastases. 4. Poorly controlled diabetes after continuous insulin therapy. 5. Significant abnormalities in laboratory values at randomization (Hb \< 90 g/L; Neutrophils \< 1.5x10\^9/L; Platelets \< 75x10\^9/L; ALT/AST \> 2.5xULN; Bilirubin \> 1.5xULN; eGFR \< 60 mL/min/1.73m\^2) . 6. Severe cardiopulmonary disease or high-risk conditions. 7. Prior therapy with any immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1). 8. Intolerance to anti-PD-1 monoclonal antibody or dandelion extracts. 9. History of severe drug allergies. 10. Factors affecting drug intake/absorption (e.g., swallowing difficulty, chronic diarrhea). 11. Concurrent psychiatric or neurological conditions